Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.37 |
| ▸ | CNR2 | P34972 | 8/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752534 | 0.90 | CTSL (0.38) | CNR1CNR2CTSLADRB2ADRB3 | |
| SCHEMBL5752652 | 0.90 | CTSL (0.38) | CNR1CNR2CTSLADRB2ADRB3 | |
| SCHEMBL5752403 | 0.87 | CTSL (0.36) | CNR1CNR2CTSLADRB2ADRB3 | |
| SCHEMBL5751663 | 0.86 | CTSL (0.39) | CTSL | |
| SCHEMBL5750071 | 0.86 | CTSL (0.37) | CNR1CNR2CTSLADRB3ADRB1 | |
| SCHEMBL5752438 | 0.85 | CTSL (0.36) | CNR2CTSL | |
| SCHEMBL5748991 | 0.84 | UGCG (0.36) | CNR1CNR2CTSLADRB3ADRB1 | |
| SCHEMBL5752146 | 0.81 | CTSL (0.37) | CTSLADRB2ADRB3ADRB1ADRA1D | |
| SCHEMBL5751951 | 0.80 | PTGER4 (0.40) | CNR1 | |
| SCHEMBL5754364 | 0.80 | CNR1 (0.40) | CNR1CNR2ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | CNR1 401/4885CNR2 485/4885CTSL 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.